---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-029564"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:26:31.198845+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics Appoints Paul Varki as Chief Legal Officer; Grants Inducement Stock Option

## Summary
- Paul Varki appointed Chief Legal Officer effective June 24, 2024; 20+ years pharma/biotech legal experience.
- Compensation includes $465K base salary, up to 40% target bonus, $50K sign-on cash award (12-month clawback).
- Inducement option to purchase 150,000 shares vesting over 4 years (1-year cliff); exercise price set at June 24 close.
- Varki previously US General Counsel at Idorsia, SVP/GC at Braeburn/Egalet, and 12 years at GSK.
- Severance: 9 months salary (12 on change in control), pro-rated bonus, accelerated option vesting, 12 months COBRA.

## SEC filing metadata
- accession: 0001628280-24-029564
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024029564/0001628280-24-029564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024029564/avtx-20240624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-029564
- JSON: https://secwatch.observer/filing/0001628280-24-029564.json
- Plain text: https://secwatch.observer/filing/0001628280-24-029564.txt

## Key facts
- Executive change
  Paul Varki was appointed as Chief Legal Officer at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Legal Officer
  source text: On June 24, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Paul Varki as Chief Legal Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828024029564/0001628280-24-029564-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.